Lei H, Chao L, Miao T, et al. - By retrospectively examining data related to children who received intranasal dexmedetomidine sedation for non-invasive investigations at the Kunming Children's Hospital between October 2017 and August 2018, researchers determined the incidence of bradycardia in this pediatric population and also explored the associated risk factors. There were 9,984 children who qualified for inclusion, of these, 228 (2.3%) developed bradycardia. A higher incidence of bradycardia was noted in the group that received additional dose of dexmedetomidine vs the group that did not receive additional dose. An independent link with the development of bradycardia was displayed only by the male gender, on multivariate logistic regression. Following the sole use of intranasal dexmedetomidine sedation in children, the estimated overall incidence of bradycardia was 2.3%. A 1.48-fold higher risk of bradycardia was observed in male children. However, blood pressure within the normal range was detected in children who developed bradycardia. An effective strategy to manage intranasal dexmedetomidine sedation-induced bradycardia can be a simple wake-up.